Waters Corporation $WAT Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC reduced its stake in shares of Waters Corporation (NYSE:WAT) by 92.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,933 shares of the medical instruments supplier’s stock after selling 38,275 shares during the quarter. Intech Investment Management LLC’s holdings in Waters were worth $1,114,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pinnacle Associates Ltd. grew its position in Waters by 0.3% during the fourth quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock worth $2,890,000 after buying an additional 26 shares during the period. Exencial Wealth Advisors LLC grew its position in Waters by 1.7% during the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock worth $638,000 after buying an additional 28 shares during the period. Rosenberg Matthew Hamilton grew its position in Waters by 8.8% during the fourth quarter. Rosenberg Matthew Hamilton now owns 359 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 29 shares during the period. Clearstead Advisors LLC grew its position in Waters by 5.1% during the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock worth $234,000 after buying an additional 30 shares during the period. Finally, Integrated Wealth Concepts LLC grew its position in Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 30 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Waters Stock Down 2.9%

Shares of NYSE WAT opened at $365.74 on Friday. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $414.15. The company has a market capitalization of $35.91 billion, a PE ratio of 46.47, a price-to-earnings-growth ratio of 2.21 and a beta of 1.21. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The firm’s 50-day moving average is $331.04 and its two-hundred day moving average is $350.91.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company’s revenue was up 91.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts anticipate that Waters Corporation will post 14.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WAT has been the topic of several recent research reports. Guggenheim reaffirmed a “buy” rating and issued a $440.00 price target on shares of Waters in a report on Tuesday, February 10th. The Goldman Sachs Group raised shares of Waters to a “strong-buy” rating in a report on Wednesday, April 1st. JPMorgan Chase & Co. upped their price target on shares of Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Citigroup initiated coverage on shares of Waters in a report on Tuesday, February 10th. They issued a “buy” rating and a $425.00 price target on the stock. Finally, Wolfe Research initiated coverage on shares of Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Waters has an average rating of “Moderate Buy” and a consensus price target of $394.24.

Insider Buying and Selling at Waters

In other news, Director Wei Jiang acquired 500 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was acquired at an average price of $289.46 per share, with a total value of $144,730.00. Following the completion of the transaction, the director directly owned 3,441 shares in the company, valued at approximately $996,031.86. This represents a 17.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.